Montana Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• ACCEL Lite: VESALIUS-CV Trial: Effect of Evolocumab in Patients at CV Risk without Prior MI or Stroke
  In this interview, Nanette Kass Wenger MD, MACC and Erin A. Bohula, MD, FACC discuss the VESALIUS-CV Trial: Effect of Evolocumab in Patients at CV Risk without Prior MI or Stroke.
• CORALreef Lipids: Oral PCSK9 Inhibitor Enlicitide Reduces LDL-C in High-Risk Patients
  Enlicitide decanoate, an oral PCSK9 inhibitor, significantly reduced LDL-C levels in patients with a history of or at risk for a first atherosclerotic cardiovascular disease (ASCVD) event, according to results of the CORALreef Lipids trial published Feb. 4 in the NEJM.
• To β or Not to β? Insights From the BETAMI-DANBLOCK Trial
  The BETAMI-DANBLOCK (Beta-Blockers after Myocardial Infarction in Patients without Heart Failure) trial results demonstrated that, in patients with recent type 1 or type 2 myocardial infarction (MI) and left ventricular ejection fraction (LVEF) ≥40%...
• Noninvasive Predictors of LA Compliance Post TMVT
  In patients with severe mitral regurgitation (MR), low left atrial (LA) reservoir strain (LASr) and prior atrial fibrillation (AFib) intervention or LA appendage (LAA) ligation may predict low invasive LA compliance and limited V-wave reduction after transcatheter mitral valve therapy (TMVT)...
• EMPHASIS: Minocycline Initiation Effective, Safe Within 72 Hours of Acute Ischemic Stroke
  Initiation of the multi-target anti-neuroinflammatory drug minocycline within 72 hours of acute ischemic stroke had a significant benefit in functional outcome compared to placebo, with no increased safety risks, according to findings from the EMPHASIS trial published Jan. 30 in The Lancet.